InMode's Revised 2023 Guidance Reflects Macro Conditions and Mixed Picture
InMode, a leading global provider of innovative medical technologies, has revised its full-year 2023 guidance due to stronger-than-expected headwinds from the current macroeconomic environment, resulting in a slowdown in platform sales, mainly in North America. The revised guidance includes a revenue range of $485 million to $495 million, non-GAAP gross margin remaining in the range of 83% to 85% for Q3 2023, non-GAAP income from operations in the range of $214 million to $218 million, and non-GAAP earnings per diluted share in the range of $2.47 to $2.50 for the full year 2023.